KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read More
Ghislaine joined Selexis in July 2015 as Genomic Director responsible for the microscopy characterization of Selexis Research Cell Banks (RCBs). In this role, she has developed a microscopy platform for transgene insertion site mapping using DNA-Fluorescence In-Situ Hybridization (FISH). She is also evaluating new technologies in Selexis’ cell line development process.
She studied biochemistry at the University of Montpellier and obtained her MSc. in molecular and cellular pharmacology at the University Paul Sabatier of Toulouse, France. Ghislaine earned her PhD in molecular biology in Geneva in the laboratory of Prof. Laemmli, where she discovered a new role for nuclear pore complexes in chromatin partitioning. This led to a publication in Cell. During her post-doctorate work at EMBL (European Molecular Biology laboratories) in Germany, she studied relations between gene expression and gene nuclear position using microscopy.
Ghislaine’s work has been published in a number of peer-reviewed journals. During her time at EMBL, she was awarded a Humboldt Fellowship.
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2023 Selexis SA. All Rights Reserved.